Nuvectis Pharma, Inc.

NasdaqCM:NVCT Stock Report

Market Cap: US$781.6m

Nuvectis Pharma Dividends and Buybacks

Dividend criteria checks 0/6

Nuvectis Pharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-2.0%

Buyback Yield

Total Shareholder Yield-2.0%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Analysis Article • Aug 20

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, Nuvectis...
Analysis Article • May 06

Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 09

We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 20

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 26

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 06

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Oct 03

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 31

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Sep 28

Nuvectis Pharma forms scientific advisory board for research and development of drugs

Nuvectis Pharma (NASDAQ:NVCT) said on Wednesday it had formed a Scientific Advisory Board that will help guide the company’s research and development strategy. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling studies.
Seeking Alpha • Aug 05

Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04

Nuvectis Pharma press release (NASDAQ:NVCT): Q2 GAAP EPS of -$0.28 misses by $0.04. Cash, cash equivalents, and short-term investments were $13.6 million as of June 30, 2022, compared to $5.7 million as of December 31, 2021. The increase of $7.9 million was primarily a result of the Company’s initial public offering in February 2022.
Seeking Alpha • Jul 27

Nuvectis Pharma declines 13%, announces $15.9M private placement

Nuvectis Pharma (NASDAQ:NVCT) enters agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1.93M shares at a price of $8.25 per share. Gross proceeds are expected to be ~$15.9M. Closing of the private placement is expected to occur on or about July 29, 2022.
Analysis Article • May 04

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if NVCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NVCT's dividend payments have been increasing.

Dividend Yield vs Market

Nuvectis Pharma Dividend Yield vs Market
How does NVCT dividend yield compare to the market?
SegmentDividend Yield
Company (NVCT)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.1%
Industry Average (Biotechs)2.1%
Analyst forecast (NVCT) (up to 3 years)n/a

Notable Dividend: Unable to evaluate NVCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NVCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate NVCT's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NVCT has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/09 19:10
End of Day Share Price 2026/09/09 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvectis Pharma, Inc. is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pete StavropoulosCantor Fitzgerald & Co.
Joseph PantginisH.C. Wainwright & Co.
I-Eh JenLaidlaw & Company (UK) Ltd